Pfizer granted FDA fast-track designation within NASH indication

This type of non-alcoholic fatty liver disease has no current treatments approved in the US, but Pfizer is now gearing up to get a medicine on the market.

US-based Pfizer can now ramp up development efforts for its combination treatment against non-alcoholic steatohepatitis (NASH) with liver fibrosis, a type of non-alcoholic fatty liver disease, as the US Food and Drug Administration (FDA) has decided to fast-track the firm’s treatment candidate, Pfizer has announced in a press release.

The fast-track designation grants Pfizer more frequent meetings with US health authorities, cutting overall case processing for the drug, which is built on two enzymes: ervogastrat and clesacostat.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs